Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 21, 2008 Brian Lawler	Regeneron's Results Clearing Up The drugmaker presents new data on a compelling candidate for macular degeneration treatment.
The Motley Fool October 2, 2007 Brian Orelli	Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data.
The Motley Fool February 28, 2011 Brian Orelli	Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience.
The Motley Fool December 27, 2010 Brian Orelli	Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline.
The Motley Fool November 22, 2010 Travis Hoium	Regeneron Pharmaceuticals Shares Popped: What You Need to Know Regeneron Pharmaceuticals shares jumped 16% today after the company announced results from VEGF Trap-Eye testing.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
The Motley Fool February 29, 2008 Brian Lawler	Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease.
The Motley Fool June 16, 2011 Brian Orelli	No Poke in the Eye Here What's the biggest sign that the Food and Drug Administration is all set to approve Regeneron Pharmaceuticals' Eylea? The briefing documents for the advisory committee contained a proposed version of the label.
The Motley Fool June 9, 2010 Brian Orelli	The Drug Passed, but the Stock Fell? Regeneron only bats .500.
The Motley Fool November 19, 2011 Luke Timmerman	Regeneron Wins FDA Approval for Macular-Degeneration Drug The company can begin selling Eylea, which treats the leading cause of blindness in the elderly.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
The Motley Fool November 11, 2009 Brian Orelli	Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis.
The Motley Fool January 11, 2012 Brian Orelli	A Year's Worth of Sales in 1 Month Regeneron's Eylea hits the gates running.
The Motley Fool September 14, 2009 Brian Orelli	More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer.
The Motley Fool April 29, 2011 Cindy Johnson	Regeneron Pharmaceuticals Shares Plunged: What You Need to Know Regeneron Pharmaceuticals dropped 12% in intraday trading today after an analyst at RBC Capital downgraded the stock from outperform to sector perform.
The Motley Fool September 2, 2011 Brian D. Pacampara	Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of drugmaker Regeneron Pharmaceuticals popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related macular degeneration treatment Avastin led to vision loss in several California patients.
The Motley Fool August 22, 2005 Rich Duprey	Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies.
The Motley Fool May 24, 2005 Charly Travers	Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
The Motley Fool November 21, 2011 Brian Orelli	This Biotech Has Almost Everything Going for It Fewer injections into the eye and lower cost than the other FDA-approved drug: What's not to like about Regeneron Pharmaceuticals' Eylea, which was approved on Friday?
BusinessWeek August 16, 2004 Arlene Weintraub	The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near.
The Motley Fool August 30, 2007 Brian Lawler	ImClone's Healthy Pipeline With three new molecules in phase 2 testing and another two in phase 1 testing by the end of the year, ImClone may not be completely reliant on Erbitux for its fortunes in the coming years.
Managed Care March 2005 Thomas Morrow	Aptamers: Slowing Progression of AMD A single strand of nucleic acid may hold the key to treating the leading cause of severe vision loss and blindness resulting from age-related macular degeneration.
Chemistry World January 13, 2011 Andrew Turley	UK tilts towards appraisal of Avastin as eye drug The UK is moving closer to opening up the National Health Service to cancer drug Avastin (bevacizumab) for the treatment of eye conditions, such as age-related macular degeneration.
The Motley Fool April 29, 2005 Tim Hanson	Genentech's Promising Future Cancer drug Avastin is finding new uses. How will outside forces affect its potential? Investors take note.
Managed Care January 2004 Thomas Morrow	Choking Off a Tumor's Blood Supply Angiogenesis blockade is a 30-year-old concept, but it will soon make the leap from lab bench to pharmacy shelf.
The Motley Fool December 31, 2010 Brian Orelli	CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool November 21, 2011 David Williamson	Market Volatility = Biotech Opportunity Gilead buys Pharmasset, Spectrum gets a break, and Eylea's approved.
Chemistry World September 24, 2014 Phillip Broadwith	Review says cheaper drug is safe for eye disease Researchers have added weight to the argument that health services should use the cancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration, instead of the more expensive Lucentis (ranibizumab).
The Motley Fool January 3, 2005 Rich Duprey	Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA.
The Motley Fool August 18, 2011 Brian Orelli	A Poke in the Eye From the FDA FDA extends its review of Regeneron Pharmaceuticals' macular degeneration drug by three months.
The Motley Fool March 17, 2011 Brian Orelli	Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping.
The Motley Fool October 14, 2011 Sean Williams	7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma...
Pharmaceutical Executive December 1, 2005 Ron Feemster	The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc.
Bio-IT World Jul/Aug 2006	News Blast Health Solutions... Rna Interference... HIV Triple Combo...
The Motley Fool November 17, 2009 Dave Mock	A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst.
BusinessWeek May 24, 2004 Arlene Weintraub	Regenerative Medicine's Slow Start Scientists think proteins that spur the body to heal could make powerful drugs, but harnessing that potential has been tough
The Motley Fool June 20, 2011 Brian Orelli	See Drug, Approve Drug An approval of Regeneron's macular degeneration Eylea looks likely.
The Motley Fool July 23, 2011	Regeneron Pharmaceuticals Earnings Preview Regeneron Pharmaceuticals will unveil its latest earnings on Wednesday, July 27.
The Motley Fool August 27, 2010 Travers & Jayson	The Most Important Thing about Regeneron Pharmaceuticals Stop obsessing about the science.
The Motley Fool November 24, 2009 Brian Orelli	4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc.
The Motley Fool February 7, 2011 Sean Williams	3 Stocks That Short-Sellers Love Could short-sellers be trying to tell us something we don't already know about these stocks?
The Motley Fool May 29, 2010 Kris Eddy	The Motley Fool's Weekly Editors' Picks Netflix hits $100... Orphan drugs equals big opportunity... Investing begins at 65... Garmin's last gasp...
The Motley Fool January 10, 2012 Travis Hoium	Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of Regeneron Pharmaceuticals jumped 13% today after the company said sales of Eylea were strong in the fourth quarter.
Pharmaceutical Executive October 1, 2011 William Looney	Curative Powers of Collaboration Napoleone Ferrara's career in medicine is an illustration of the maxim that stretching the boundaries of science is a leap in the dark.
The Motley Fool January 15, 2012 Brian Orelli	3 Lessons From the J.P. Morgan Health-Care Confab After 30 years, the conference still offers useful takeaways. This years: Some biotechs never die... In the United States, more people die from flu each year than die from HIV AIDS... Drug launches are back (maybe)...
The Motley Fool November 12, 2009 Kris Eddy	Drug Companies Should Think Smaller Sanofi-aventis looks to break R&D into smaller chunks; their collaboration with Regeneron Pharmaceuticals is a good example of the new strategy.
Pharmaceutical Executive June 1, 2013 Ben Comer	Regeneron: New York State of Mind Led by two New Yorkers with a mindset that marries novel scientific insights to the processing power of novel technologies, Regeneron's success is a revolutionary challenge to the industry status quo.